Peter Nählstedt has extensive experience in developing global growth companies in Life Science. He was appointed to SenzaGens board of directors in 2018 and has during this time also worked operatively in the company with its commercial development. He has in recent years lead several international growth projects in Life Sciences as a consultant and a board professional. His most recent operative assignment was as CEO of Probi AB. His past experiences includes management positions with Trelleborg Marine Systems and GE Healthcare.
Education: MSc in Chemical Engineering, BSc in Business Administration.
Shareholding: 1 622 shares and 25 000 warrants.
Marianne Olsson has 25 years of experience from Lund University where she has worked as a department economist, economist and most recently as administrative manager at the Department of Immunotechnology. In addition, Marianne has been a member of the Board of the Faculty of Engineering LTH at Lund University, as well as a member of the management and Department Board at the Department of Immunotechnology.
Education: Certified Financial Manager via FAR.
Shareholding: 114 285 shares and 50 000 warrants.
Anna Chérouvrier Hansson
Anna has extensive experience from marketing, sales and business development from Camurus, Novo Nordisk, Gambro and DuPont among others. In addition, Anna has been a partner at Zitha Consulting, focusing on commercialisation strategy in the pharmaceutical industry and head of Life Science investments at Invest in Skåne.
Education: MSc in European Business Administration and Business Law, BSc in Business Administration.
Shareholding: 19 153 shares and 65 000 warrants.
Tina Dackemark Lawesson
Tina Dackemark Lawesson has long and broad experience from marketing, IR and communication at life science and technology companies in the build-up and growth phase. She has previously held similar positions at INVISIO, CellaVision and Enzymatica among others.
Education: Bachelor of Education (Languages) as well as studies in Journalism.
Shareholding: 1 000 shares and 65 000 warrants.
Henrik Johansson has more than 10 years of experience of research and development within the fields of cell and molecular biology. He is specialized in in vitro assays for predictive immunotoxicology and is a co-developer of the GARD technology platform, which was first described in detail in his doctoral thesis.
Education: MSc. in Biotechnology Engineering, PhD in Immunotechnology.
Shareholding: 526 shares and 10 000 warrants.
For the past 20 years, Åsa Nyhlén has been responsible for laboratory services in the pharmaceuticals, medical devices and food industries. Åsa has extensive experience of working with international lab partners and building effective and innovative lab organizations. Her past experience includes management positions with Novo Nordisk, Dako and BioGaia.
Education: Msc. in molecular biology.
Shareholding: 6 300 shares and 50 000 warrants.
Helen Olsson has over 20 years of experience in organization development, change management, and both operational and strategic HR, including as VP HR at BioGaia.
Education: Degree in behavioral science.
Shareholding: 1 000 shares.
Mikael Wahlgren has previously served as group general counsel for the Alfa Laval Group, corporate counsel for several multinational companies, and as legal counsel for several life science companies. He has been employed with law firm Lindmark Welinder since 2021 where he serves as legal adviser, arbitrator and mediator.
Shareholding: 8 571 shares and 11 500 warrants through companies.